Comparison of longitudinal Aβ in nondemented elderly and Down syndrome
暂无分享,去创建一个
Sterling C. Johnson | Charles M. Laymon | Ann D. Cohen | William E. Klunk | Chester A. Mathis | Julie C. Price | Stewart J. Anderson | Howard J. Aizenstein | Davneet S. Minhas | Benjamin L. Handen | Dana L. Tudorascu | Zheming Yu | Patrick J. Lao | Brian J. Lopresti | Diane Comer | D. Minhas | C. Laymon | W. Klunk | C. Mathis | J. Price | B. Snitz | H. Aizenstein | B. Christian | B. Lopresti | S. Anderson | A. Cohen | D. Tudorascu | B. Handen | S. Hartley | Sterling Johnson | Beth E. Snitz | D. Comer | Patrick Lao | Sigan Hartley | Brad T. Christian | Zheming Yu | S. Johnson | J. Price | J. Price
[1] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[2] Bedda L. Rosario,et al. Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve , 2009, The Journal of Neuroscience.
[3] C. Rowe,et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[4] D. Selkoe,et al. Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.
[5] Tammie L. S. Benzinger,et al. Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers , 2013, Science Translational Medicine.
[6] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[7] Sterling C. Johnson,et al. The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B , 2016, Alzheimer's & Dementia.
[8] Daniel Bandy,et al. Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.
[9] S. Wisniewski,et al. Research evaluation and diagnosis of possible Alzheimer’s disease over the last two decades: II , 2000, Neurology.
[10] D. Mann,et al. Diffuse Plaques in the Cerebellum and Corpus Striatum in Down's Syndrome Contain Amyloid β Protein (Aβ) only in the Form of Aβ42(43) , 1996 .
[11] M. Mintun,et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.
[12] M. Kenward,et al. Small sample inference for fixed effects from restricted maximum likelihood. , 1997, Biometrics.
[13] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[14] Jeffrey A. James,et al. Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease , 2014, Neurology.
[15] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[16] H. Braak,et al. Alzheimer's Disease: Striatal Amyloid Deposits and Neurofibrillary Changes , 1990, Journal of neuropathology and experimental neurology.
[17] Lisa A. Weissfeld,et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET , 2010, NeuroImage.
[18] O L Lopez,et al. Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I , 2000, Neurology.
[19] W. Klunk,et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B , 2012, Alzheimer's & Dementia.
[20] A. Gedye,et al. Dementia Scale for Down Syndrome , 2009 .
[21] H. Wiśniewski,et al. Early amyloid -β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of β-peptide in Alzheimer's disease and Down's syndrome brain , 1995, Neuroscience Letters.
[22] Clifford R. Jack,et al. Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE , 2017, NeuroImage.
[23] D. Price,et al. Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.
[24] W. Klunk,et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition , 2018, Alzheimer's & Dementia.
[25] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[26] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] C. Lemere,et al. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. , 2015, Current Alzheimer research.
[28] C. Jack,et al. Age and sex specific prevalences of cerebral β-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50-95 years: a cross-sectional study , 2017, The Lancet Neurology.
[29] John Seibyl,et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.
[30] Sterling C. Johnson,et al. Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population , 2017, Alzheimer's & dementia.
[31] Pritam Das,et al. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. , 2014, Brain : a journal of neurology.
[32] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.